Refractory Lung Non-Small Cell Carcinoma (DBCOND0115393)
Identifiers
- Synonyms
- Refractory Non-small cell lung cancer
Associated Data
- Indicated Drugs and Targets
Drug Description Targets Vemurafenib A kinase inhibitor used to treat patients with Erdheim-Chester Disease who have the BRAF V600 mutation, and melanoma in patients who have the BRAF V600E mutation.- Albumincarrier
- Alpha-1-acid glycoprotein 1carrier
- Cytochrome P450 1A2enzyme
- Cytochrome P450 2D6enzyme
- Cytochrome P450 3A4enzyme
- Serine/threonine-protein kinase B-raftarget
- Multidrug resistance-associated protein 1transporter
- Broad substrate specificity ATP-binding cassette transporter ABCG2transporter
- Cytochrome P450 2C9enzyme
- Cytochrome P450 2C8enzyme
- Cytochrome P450 2B6enzyme
- ATP-dependent translocase ABCB1transporter
- Clinical Trials
Identifier Title Drug(s) Purpose Phase Status NCT06015724 Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer treatment 2 recruiting NCT04285671 Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer treatment 1 / 2 active_not_recruiting NCT04007744 Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors treatment 1 recruiting NCT03600701 Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer treatment 2 active_not_recruiting NCT04081688 Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC treatment 1 active_not_recruiting NCT05334329 Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors treatment 1 active_not_recruiting